An individualized and customized approach should be used when selecting antibiotics for treatment of
Acinetobacter infections.
The report provides a snapshot of the global therapeutic landscape of
Acinetobacter InfectionsTill the early 1970s, nosocomial
Acinetobacter infections were successfully treated with antibiotics like gentamicin, minocycline, nalidixic acid and ampicillin3.
According to studies,
acinetobacter infections are not uncommon in preterm ICUs and there are reports of infant deaths in other countries.
Resistance to carbapenem class of antibiotics makes multidrug resistant
acinetobacter infections difficult to treat.
baumannii keeps on changing, local surveillance studies conducted at regular intervals will help in deciding the most adequate therapy for
Acinetobacter infections.
Worldwide, treatment of multidrug resistant
Acinetobacter infections poses a great therapeutic challenge to clinicians.
Until further data become available, no firm recommendations can be made with regard to the testing or clinical utility of tigecycline, either alone or in combination with polymyxin, the carbapenems (regardless of the mode of delivery), rifampicin (or possibly fosfomycin) for life-threatening MDR
Acinetobacter infections.
The major challenge in treating
Acinetobacter infections is that most strains are MDR.
Clinical and molecular epidemiology of
acinetobacter infections sensitive only to polymyxin B and sulbactam.
Coverage includes avian influenza, severe acute respiratory syndrome (SARS), changing patterns of respiratory viral infections in transplant recipients, West Nile virus, emergence of novel retroviruses, community- associated methicillin-resistant Staphylococcus aureus, the emerging role of Klebsiella in liver abscess, zygomycosis, emerging food- and waterborne protozoan diseases, multidrug-resistant
Acinetobacter infections in US military personnel, and adverse events in smallpox vaccination.
SAN FRANCISCO -- Antibiotic resistance increased rapidly in nosocomial
Acinetobacter infections from 1994 to 2004, growing almost fourfold, according to a report from the Centers for Disease Control and Prevention.
